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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder characterized by epistaxis,
arteriovenous malformations, and telangiectases. The majority of the patients have a mutation in the coding region
of the activin A receptor type II-like 1 (ACVRL1) or Endoglin (ENG) gene. However, in approximately 15% of cases,
sequencing analysis and deletion/duplication testing fail to identify mutations in the coding regions of these
genes. Knowing its vital role in transcription and translation control, we were prompted to investigate the
5’untranslated region (UTR) of ENG.
Methods and Results: We sequenced the 5’UTR of ENG for 154 HHT patients without mutations in ENG or ACVRL1
coding regions. We found a mutation (c.-127C > T), which is predicted to affect translation initiation and alter the
reading frame of endoglin. This mutation was found in a family with linkage to the ENG, as well as in three other
patients, one of which had an affected sibling with the same mutation. In vitro expression studies showed that a
construct with the c.-127C > T mutation alters the translation and decreases the level of the endoglin protein. In
addition, a c.-9G > A mutation was found in three patients, one of whom was homozygous for this mutation.
Expression studies showed decreased protein levels suggesting that the c.-9G > A is a hypomorphic mutation.
Conclusions: Our results emphasize the need for the inclusion of the 5’UTR region of ENG in clinical testing for
HHT.
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Background
Hereditary hemorrhagic telangiectasia (HHT) is an auto-
somal dominant vascular dysplasia characterized by
epistaxis, telangiectasesand arteriovenous malformations
(AVMs). AVMs that occur in the lungs, brain, or gastro-
intestinal tract can cause life-threatening complications
secondary to either hemorrhage or the shunting of
blood through abnormal blood vessels [1-5]. HHT is
diagnosed on clinical grounds when an individual has
three or more of the following diagnostic criteria: spon-
taneous- recurrent epistaxis, mucocutaneous telangiec-
tases (especially on tongue, lips, oral mucosa, fingers,
and nose), internal AVMs (pulmonary, cerebral, hepatic,
gastrointestinal, spinal), and a first degree relative with
HHT. The diagnosis is considered possible or suspected
when two criteria are present and unlikely when there
are fewer than two [6]. HHT is a clinically heteroge-
neous disorder, with symptoms often differing among
family members, making the disorder difficult to diag-
nose [7,8].
HHT is a genetically heterogeneous disorder for which
mutations in more than three genes cause disease. The
majority of the clinically diagnosed HHT patients have a
mutation in the coding regions of the Endoglin (ENG)
gene or activin A receptor type II-like 1 (ACVRL1)g e n e
[9-15], leading to HHT1 or HHT2, respectively. Muta-
tions in SMAD4 have been detected in approximately
2% of patients with HHT and cause HHT and juvenile
polyposis (JP/HHT) syndrome [16]. At least two addi-
tional genes, at 5q31.3-32 (HHT3) [17] and 7p14
(HHT4) [18], have been suggested by linkage studies. * Correspondence: pinar.bayrak-toydemir@aruplab.com
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sequencing of ACVRL1 and ENG coding regions, large
deletion/duplication analysis, and if no mutation is iden-
tified, analysis of SMAD4. Approximately 15% of HHT
cases have no mutations found in coding regions of
these three genes [19,20]. But linkage studies in some of
these families still implicate the ENG locus (PBT unpub-
lished data). This is possible if mutations are in the non-
coding regions such as introns or regulatory parts of the
ENG gene. In particular, mutations in the 5’UTR may
explain the pathogenesis of the disorder in some cases,
since most of the transcription and/or translation pro-
tein complexes bind and regulate expression from the
5’UTR of the gene [21,22] Based on this information,
combined with supportive linkage data to the ENG,w e
decided to investigate the role of the 5’UTR region of
ENG. We sequenced this region in 154 unrelated HHT
patients who do not carry a disease causing mutation in
the coding region of the ACVRL1 and ENG genes by
sequencing and deletion/duplication analyses.
Methods
Subjects
Our study group consists of 154 unrelated HHT cases.
Cases included were those with two or more HHT clini-
cal diagnostic criteria reported by their physician and
negative mutation results. Information regarding HHT
symptoms and manifestations was obtained from a dis-
order specific history form completed by ordering physi-
cians and/or by assessment at the HHT Center at the
University of Utah. Cases selected were negative for
mutations by sequencing of the coding region and
intron/exon boundaries, and also deletion/duplication
analysis of the ACVRL1 and ENG genes. This study was
approved by the Institutional Review Board of the Uni-
versity of Utah. The control group consisted of 134
healthy individuals. Based on the mutation results from
the study group in Utah, a later collaboration was estab-
lished with the Spanish HHT Genetics group to include
one additional family with the c.-127C > T mutation.
Although this family is not part of 154 patients’ cohort,
it has been included to provide additional clinical corre-
lation for this mutation.
Sequencing
Genomic DNA was extracted via automated Magna
Pure (Roche Diagnostics, Indianapolis, IN) from whole
blood. Primers were designed to amplify the entire
5’UTR region of ENG, BigDye sequencing chemistry was
used to sequence the PCR products in both directions
using the ABI 3730xl DNA analyzer (Applied Biosys-
tems, Foster City, CA). The sequences were analyzed by
the Mutation Surveyor program (Softgenetics, State Col-
lege, PA). The variants detected were compared to the
NCBI dbSNP databases to determine if the nucleotide
change found in our study had previously been reported
in healthy individuals.
Plasmids
The 3-kb fragment of human endoglin cDNA cloned in
pUC13 was previously described [23]. This plasmid was
used as a template to generate the single endoglin
mutants c.-9G > A and c.-127C > T. The mutant c.-9G
> A was amplified using the following primers: 5’-
AGGCCCCCACATGGACAGCAT -3’(Forward) and 5’-
ATGCTGTCCATGTGGGGGCCT -3’ (Reverse). The
mutant c.-127C > T was amplified using the following
primers: 5’- TGGAGCAGGGATGCCGTCGCT -3’ (For-
ward) and 5’-AGCGACGGCATCCCTGCTCCA -3’
(Reverse). The mutant c.-205A > C was amplified using
the following primers: 5’- TTCGGACAGCCACTC-
CAGCCC - 3’ (Forward) and 5’-
GGGCTGGAGTGGCTGTCCGAA - 3’ (Reverse). Then
the single endoglin mutant c.-9G > A was used as a
template to generate the double mutant c.-9G > A and
c.1A > G in the presence of following primers: 5’- ATG-
GACAGCGTGGACCGCGGC -3’ (Forward) and 5’-
GCCGCGGTCCACGCTGTCCAT -3’ (Reverse). The
resulting pUC13 plasmids containing wild type and
mutant sequences were digested with EcoRI and the 3-
kb endoglin fragments were inserted into the pCEXV
expression vector [23]. The expression vector 437/586-
Endo encoding a hemagglutinin (HA)-tagged truncated
version of human endoglin in pDisplay vector (Invitro-
gen) has been reported [24].
Cell culture, transfections and western blot analyses
The monkey kidney COS-7 cell line was cultured in
DMEM supplemented with 10% heat inactivated fetal
calf serum, 2 mM L-glutamine, penicillin (100 U/ml),
and gentamycin (25 mg/ml). For functional studies, cell
transfections were carried out using SuperFect Reagent
(Qiagen, Hilden, Germany) as vehicle for plasmids,
according to the manufacturer’s instructions. Cells were
cotransfected with endoglin constructs in pCEXV and
HA-437/586-Endo in pDisplay to correct for transfec-
tion efficiency. Twenty four hours after transfection,
cells were lysed in lysis buffer and subjected to immuno-
blotting with anti-endoglin (clone P4A4; DSHB, Univer-
sity of Iowa), anti-HA (clone 12CA5; Boehringer
Mannheim) or anti-actin (clone AC-15; Sigma) mouse
monoclonal antibodies [24]. The presence of the specific
proteins was revealed with horseradish peroxidase con-
jugated anti-mouse IgG (Dako, Barcelona, Spain) and
the reaction was developed by addition of supersignal
chemiluminescent substrate (Pierce, Thermo Scientific,
Spain). Protein bands were visualized with a Chemi-
Doc™ XRS+ equipment (Bio-Rad, Madrid, Spain) and
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software.
Results
To understand the role of 5’UTR of ENG we sequenced
the noncoding region of exon 1 of ENG for 154 unre-
lated patients/probands with 2 or more clinical diagnos-
tic criteria. These results revealed three sequence
changes; c.-127C > T, c.-205A > C, and c.-9G > A. Out
of 154, three had c.-127C > T, one had c.-205A > C,
and three had c.-9G > A mutation. When available, pro-
bands’ family members were studied to see if the muta-
tion tracked with the disease. For the c.-127C > T
mutation, we included a family from Northern Spain to
provide additional information about this mutation.
Clinical manifestations of the probands and their evalu-
ated family members are summarized in Table 1. Cases
listed as having no solid organ involvement had screen-
ing for pulmonary AVMs (PAVMs) by contrast echocar-
diogram and/or chest computed tomography (CT) and
for brain AVMs by a contrasted magnetic resonance
imaging (MRI), and physical examination and medical
history that did not suggest other AVMs. Sequencing
results of 134 healthy control samples did not reveal any
sequence change in the 5’UTR of ENG.
The c.-127C > T heterozygous change was found in
three out of the 154 clincal HHT cases and in one
case from Northern Spain (family 4). For one of these
cases (family 1), an affected sibling was also available
a n dw a sf o u n dt ob ep o s i t i v ef o rt h em u t a t i o n .T w oo f
the siblings met clinical diagnostic criteria with fre-
quent epistaxis, typical telagiectasia, PAVMs, and gas-
trointestinal (GI) telangiectasia. The second patient
(proband 2) was a member of a family (family 2) linked
to the ENG by locus specific short tandem repeat
(STR) markers. The ACVRL1 region was excluded in
this family (data not shown). There were 5 clinically
affected family members available for the family segre-
gation study (Figure 1a). The mutation is carried by all
studied family members affected with HHT. Although
our 67 year old proband did not have any solid organ
involvement, an 18 year old grandniece had a spinal
AVM, an 8 year old grandnephew had cerebral AVMs
(CAVMs), and three other affected family members
had pulmonary AVMs (PAVMs). Family members of
the third patient (proband 3) were not available for
family segregation study. Proband 3 had PAVMs, tel-
angiectases on the face and 2-6 episodes/week of epis-
taxis. The c.-127C > T mutation was also found in one
family proband from Northern Spain (family 4). No
other affected family member, including his deceased
mother, was available for a segregation study. But the
mutation was not seen in hisu n a f f e c t e df a t h e ro r
brother (Figure 1b).
The sequence ideogram and neighboring sequences of
the c.-127C > T mutation are shown in Figure 2a. This
sequence alteration creates a potential AUG initiation
codon at base -127 from translation initiation of the
ENG gene. The c.-127C > T change is not reported in
the NCBI dbSNP database. NetStart 1.0 Prediction Pro-
gram [25] predicts that this mutation creates a new
translation start site (TIS) with an altered reading frame
(Figures 2c and 3). Interestingly, the sequence surround-
ing the new TIS fits well with the Kozak consensus and
other motifs that play a major role in the initiation of
the translation process [26,27], suggesting that this new
TIS may be functionally active. Because translation
usually initiates solely at the first ATG codon in an ade-
quate context, it is likely that the new TIS at -126/-128
is competing advantageously with the constitutive TIS at
+1. To test this hypothesis, we generated a mutant con-
struct in a full length endoglin cDNA, that contains the
5’UTR [23], where the c.-127C > T change was intro-
duced (Figure 3). The wild type and mutant constructs
were cloned into an expression vector and the levels of
endoglin protein expression were assessed by transient
transfection in the monkey cell line COS-7. As shown in
Figure 4, we found that protein expression levels of the
mutant endoglin construct c.-127C > T were markedly
reduced (74%) with respect to the wild type construct.
This result suggests that the c.-127C > T mutation gen-
erates a functional TIS out of frame that interferes with
translation initiation of the constitutive ATG at +1,
leading to endoglin haploinsufficiency.
The c.-9G > A mutation (Figure 2b) was found in
three HHT families. Three family members were avail-
able from family 6 (Figure 1c). All carried the mutation
and had infrequent epistaxis and telangiectases with no
solid organ involvement. Proband 7 was 27 years old
when she was examined. She had a few telangiectases
on her face and infrequent epistaxis only during her
childhood. She did not have any solid organ involve-
ment. There were no other family members available for
this study. All of these patient’s clinical findings were
relatively mild, none of them had solid organ involve-
ment or severe/frequent epistaxis causing anemia or
blood transfusion.
Proband 8 was found to be homozygous for c.-9G > A
mutation (Figure 2b). In order to confirm this result and
to rule out primer binding site polymorphisms, this
region was sequenced with three different primer sets.
Multiplex ligation dependent probe amplification
(MLPA) method was used to test for a large deletion of
the region. MLPA results and sequencing with different
primer sets confirmed that proband 8 carries two copies
of the mutant allele for this region (data not shown).
Proband 8 had daily epistaxis and telangiectases on his
lips, tongue, ear, hands, face and pharynx. His son’s
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had a few telangiectases on his lips and face, and epis-
taxis. Neither of them had solid organ involvement. His
son was not available for molecular testing; however, he
is an obligate carrier for the mutation as his father is
homozygous. The parents of the proband were deceased,
thus not available for examination or testing. Neither
was known by the proband to have nosebleeds or telan-
giectasia. The mother reportedly died at age 42 of
tuberculosis and father of a myocardial infarct in the
decade of his 60s.
The c.-9G > A mutation is not reported in NCBI
dbSNP database, nor it was seen in our control group.
This mutation is predicted to create a new TIS with the
same reading frame as endoglin and a resulting protein
which contains three additional amino acids in the lea-
der sequence (Figure 3). Of note, the length of the
resulting leader sequence (28 amino acids) is within the
Table 1 Molecular results and clinical findings in probands and family members
Family
#
Individual (age at
examination)
Molecular Result Telangiectasia Epistaxis Solid Organ
Involvement
Segregation
in the
family
Family
1
Proband (74 yo) c.-127C > T hands, lips, cheeks, palate, ears 6-8/day GI telangiectases,
PAVM
Yes
Brother (74 yo) c.-127C > T hands, lips 2-3/day GI telangiectases,
PAVM
Family
2
Proband (67 yo) c.-127C > T hands, ear, lips, tongue, palate,
conjunctivae
1-2/month none Yes
Daughter (50 yo) c.-127C > T lips, tongue, palate 1-2/week PAVMs
Son (39 yo) c.-127C > T lips, palate, ears, hands 2/week PAVM
Nephew (41 yo) c.-127C > T yes yes PAVM
Nephew (42 yo) Negative for c.-127C > T none no unknown
Grandniece (18 yo) c.-127C > T yes daily Spinal AVM
Grandnephew (8 yo) c.-127C > T unknown daily CAVM
Family
3
Proband 3 (28 yo) c.-127C > T face 2-6/week PAVM No
Family
4
Proband 4 (41 yo) c.-127C > T multiple face, hands and feet yes PAVM * NI
Unaffected father of
proband
Negative for c.-127C > T none none unknown
Unaffected brother of
proband
Negative for c.-127C > T none none unknown
Family
5
Proband 5 (10 yo) c.-205A > C hands and lip 1/month none Yes
Brother (6 yo) Negative for c.-205A > C hands 1 every 2
months
none
Father (38 yo) Negative for c.-205A > C few on hand 1 every 2
months
unknown
Mother (38 yo) c.-205A > C none none unknown
Family
6
Proband 6 (4 yo) c.-9G > A 2 face, 1 hand 2/month
(mild)
none Yes
Mother (26 yo) c.-9G > A 4 hands, 1 face 2/month
(mild)
none
Grandmother (52 yo) c.-9G > A lips, ear, face, hands 4/month
(mild)
none
Family
7
Proband 7 (27 yo) c.-9G > A few on face only in
childhood
unknown No
Family
8
Proband 8 (78 yo) c.-9G > A (homozygous) lips, tongue, ear, hands, face
and pharynx
daily none No
Son (40 yo) c.-9G > A (obligate carrier-
but not tested)
lips, face “regular”,
“bad”
none
PAVM: Pulmonary AVM
CAVM: Cerebral AVM
GI: Gastrointestinal
Unknown: has not been tested
*NI: Not informative. Based on family history it is possible that this mutation segregates in the family. However, a de novo event cannot be excluded.
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peptides in precursor proteins [28]. To assess whether
the new TIS at -9 was affecting the expression of the
endoglin protein, we generated two different mutant
constructs in a full length endoglin cDNA that contains
the 5’UTR. A single mutant contained the c.-9G > A
change of the HHT patients, while a double mutant
contained both the c.-9G > A mutation plus the c.1A >
G mutation. Functional studies of the c.-9G > A muta-
tion showed that expression of the mutant protein was
reduced approximately 20% compared to the wild type
protein (Figure 4A). To prove that the ATG at -9 was
functioning as a real TIS, the constitutive initiation site
at position 1 was abolished in the double mutant (c.-9G
> A and c.1A > G). Thus, transfection studies with this
double mutant demonstrated that the corresponding
endoglin protein was expressed, although at a much
lower level (60%), as compared to 81% with the c.-9G >
A construct. While the predicted mature endoglin pro-
tein driven by the TIS at -9 is identical to the one dri-
ven by the constitutive TIS at +1, the decreased
expression levels of endoglin with the c.-9G > A muta-
tion are likely due to a lower translation efficiency and/
or a less efficient processing of the endoglin precursor
protein through the secretory pathway. Taken together,
these results suggest that the mutation c.-9G > A
Figure 1 A. Family segregation study for family 2. The pedigree for family 2 is shown. The c.-127C > T mutation was shown to segregate
among affected individuals in this family, where 5 clinically affected family members were available for the family segregation study. 1B. Family
segregation study for family 4. The pedigree for family 4 is shown. Three family members were sequenced. Two unaffected family members
were shown to be negative for the mutation. 1C. Family segregation study for family 6. The pedigree for family 6 is shown. 3 family
members were available from family 6. All 3 carried the -127C > T mutation.
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c.-127C>T heterozygous forward sequencing result 
 
                                                                                   
c.-127C>T 
 
2B. 
c.-9G>A homozygous forward sequencing result 
                                                                                          c.-9G>A 
 
c.-9G>A heterozygous forward sequencing result 
 
                                                                                 
c.-9G>A 
 
CCC TGG GGC CAG GAC TGC TGC TGT CAC TGC CAT CCA TTG GAG CCC AGC ACC CCC TCC CCG
CCC ATC CTT CGG ACA GCA ACT CCA GCC CAG CCC CGC GTC CCT GTG TCC ACT TCT CCT GAC
CCC TCG GCC GCC ACC CCA GAA GGC TGG AGC AGG GAC GCC GTC GCT CCG GCC GCC TGC TCC
CCT CGG GTC CCC GTG CGA GCC CAC GCC GGC CCC GGT GCC CGC CCG CAG CCC TGC CAC TGG
ACA CAG GAT AAG GCC CAG CGC ACA GGC CCC CAC GTG GAC AGC ATG  GAC CGC  GGC ACG  
5´UTR  3´UTR  ORF 
-282 
-222 
-162 
-102 
-  42 
+1 
282-bp 1875-bp  604-bp 
2C. 
Endoglin cDNA (X72012; GI: 402206) 
 
Met   Asp    Arg    Gly   Thr    
*  * 
* 
* 
Figure 2 A. Sequencing results from one individual with the c.-127C > T heterozygous mutation. The forward sequence is shown. The
arrow indicates the position of the mutation. 2B. Sequencing results from two individuals (one homozygous and one heterozygous) for
the -9G > A mutation. The arrow indicates the position of the mutation. 2C. Schematic representation of endoglin mRNA. The 5’UTR, the
3’UTR and the open reading frame (ORF) are indicated. Endoglin cDNA accession number (X72012) corresponding to the 3073-bp mRNA of
endoglin [21] and the gene ID (GI, 402206) are also included. The sequence of the 5’UTR and part of the signal peptide (-282/+15) is shown.
Asterisks indicate the positions mutated in panels 2a and 2b.
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CCT CGG GTC CCC GTG CGA GCC CAC GCC GGC CCC GGT GCC CGC CCG CAG CCC TGC CAC TGG
ACA CAG GAT AAG GCC CAG CGC ACA GGC CCC CAC GTG GAC AGC ATG  GAC CGC  GGC ACG  
-162 
-102 
-  42 
+1 
Met   Asp    Arg    Gly   Thr    
* 
* 
Wild type and ATG mutant constructs 
 
5´UTR  3´UTR  ORF 
CCC TCG GCC GCC ACC CCA GAA GGC TGG AGC AGG GAT GCC GTC GCT CCG GCC GCC TGC TCC 
CCT CGG GTC CCC GTG CGA GCC CAC GCC GGC CCC GGT GCC CGC CCG CAG CCC TGC CAC TGG 
ACA CAG GAT AAG GCC CAG CGC ACA GGC CCC CAC GTG GAC AGC ATG  GAC CGC  GGC ACG  
-162 
-102 
-  42 
+1 
Met   Asp    Arg    Gly   Thr    
* 
WT 
c.1-127C>T 
c.1-9G>A; +1A>G 
New ORF  
ENG ORF  
CCC TCG GCC GCC ACC CCA GAA GGC TGG AGC AGG GAC GCC GTC GCT CCG GCC GCC TGC TCC 
CCT CGG GTC CCC GTG CGA GCC CAC GCC GGC CCC GGT GCC CGC CCG CAG CCC TGC CAC TGG 
ACA CAG GAT AAG GCC CAG CGC ACA GGC CCC CAC ATG GAC AGC ATG  GAC CGC  GGC ACG  
-162 
-102 
-  42 
+1 
Met  Asp    Ser   Met     Asp     Arg    Gly   Thr   
* 
c.1-9G>A 
ENG ORF  
                        Met     Asp     Arg     Gly   Thr   
CCC TCG GCC GCC ACC CCA GAA GGC TGG AGC AGG GAC GCC GTC GCT CCG GCC GCC TGC TCC 
CCT CGG GTC CCC GTG CGA GCC CAC GCC GGC CCC GGT GCC CGC CCG CAG CCC TGC CAC TGG 
ACA CAG GAT AAG GCC CAG CGC ACA GGC CCC CAC ATG GAC AGC GTG  GAC CGC  GGC ACG  
-162 
-102 
-  42  *  ENG ORF  
Met   Asp    Ser   Val     Asp    Arg    Gly   Thr    
Figure 3 Schematic representation of wild type and mutant versions of endoglin. The 5’UTR, the 3’UTR and the region corresponding to
the ORF are indicated (top). The sequence of wild type (WT) and mutants (c.-127C > T; c.-9G > A; c.-9G > A and +1A > G) corresponding only
to the -162/+15 region is shown. Asterisks indicate the positions of the HHT mutations of Figs. 2a and 2b. The constitutive translation initiation
(+1), the predicted translated amino acids (three letters code in green) as well as the putative translation initiation sites (brown broken arrow)
are also indicated.
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tein that is compatible with the mild effect in heterozy-
gosis and a more severe, but still classical, HHT
phenotype in homozygosis.
The c.-205A > C heterozygous variant was found in
one patient (Proband 5). Three family members were
available for study. It was not found in a brother and
father with infrequent, recurring nosebleeds and telan-
giectases in characteristic locations, but was identified in
an asymptomatic mother. This variant was not found in
dbSNP database, nor was it found in healthy controls.
However, based on in silico analyses this variant is not
predicted to have a significant effect on the regulation
of the translation or transcription. In the family segrega-
tion study this mutation does not track with symptoms
of HHT, and in silico analysis does not support patho-
genicity. Expression analysis of the mutant construct (c.-
205A > C) showed similar protein levels as the wild type
c o n s t r u c t( F i g u r e4 B )c o n f i r m i n gt h a ti ti sab e n i g n
sequence change.
Discussion
HHT is a genetically heterogeneous disease with at least
three causative genes [9-15]. 15% of clinically diagnosed
HHT cases cannot be explained by mutations in the
coding regions or exon/intron junctions of ACVRL1,
ENG,o rSMAD4 [19,20]). Yet in some families, linkage
data suggests ACVRL1 or ENG to be the causative gene.
Therefore, non-coding regions may play a role in the
disease. However, previously described mutations in
ENG were located only on the coding regions and exon-
intron junctions of the gene [29,30]. So far, no 5’UTR
mutations or deep intronic mutations have been
described. ENG promoter activity was found to be
within the upstream 400 bp region from the TIS, and an
area near the transcription initiation site of ENG was
determined to be essential for promoter function
[21,31]. We therefore chose this critical region to ana-
lyze in our unexplained HHT cases. We have identified
a5 ’UTR mutation (c.-127C > T) in 3 unrelated pro-
bands, 2 of which had family members evaluated for co-
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Figure 4 Functional analysis of ATG endoglin mutants. COS-7 cells were transfected with wild type (WT) or endoglin mutants 4A: c.-9G > A
(-9), c.-9G > A & c.+1A > G (-9&+1) or c.-127C > T (-127), and 4B: c.-205A > C (-205) in the presence of HA-437/586-Endo in pDisplay (HA-437.E)
to correct for transfection efficiency. After 24 h, cells were lysed and total cell lysates were subjected to western blot analysis using anti-endoglin,
anti-HA or anti-actin antibodies. As a loading control, the presence of actin is included. Normalized endoglin levels relative to cotransfected HA-
437/586-Endo and total actin proteins are shown in the histogram. An arbitrary value of 100 was assigned to WT endoglin. The average of six
different experiments is shown in each panel.
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from Northern Spain is also included in this study for
additional clinical description of the mutation. All
affected individuals had classical clinical findings of
HHT disease, including many with solid organ involve-
ment. The clinical findings and medical histories in
these four families are typical of HHT1 families pre-
viously reported [32]. The number of PAVMs observed
in these families with c.-127C > T mutation seems pos-
sibly greater than typical for HHT1 disease, this may
represent ascertainment bias since the majority of these
patients were seen in an HHT specialty clinic that tend
to attract patients with pulmonary AVMs for treatment
and expected variation of HHT. During the revision of
this manuscript, Kim et al reported a Korean family
with the c.-127C > T mutation, in which the proband of
the family has epistaxis and PAVM [33].
Current data suggest that most disease-causing muta-
tions in ENG result in haploinsufficiency [8,32,34-36].
T h u s ,H H Ti sa s s u m e dt or e s u l tf r o ml a c ko fs u f f i c i e n t
protein for normal function [37]. Mutations resulting in
structural alterations by misfolding and intracellular
degradation of these proteins lead to lack of surface
expression of the mutant proteins. The c.-127C > T
mutation in the 5’UTR creates a new TIS resulting in an
out-of-frame product. Translation initiation from this
novel start site predicts prematurely truncated protein
with no homology to wild type protein. This mutation
effect would be similar to any frameshift mutations seen
in the ENG, which is lack of the protein expression on
the cell surface. Expression studies confirmed that endo-
glin protein level is decreased to 26% of the wild-type
construct, a figure compatible with quantitative mea-
surements of endoglin levels in endothelial cells derived
from HHT1 patients [37]. Kozak sequences are con-
served sequences that ribosomes recognize as the start
of translation of the protein [26,27]. The original TIS of
the ENG gene does not have a strong Kozak consensus
sequence. This and the fact that translation preferen-
tially initiates at the first ATG codon suggest that the
new TIS is competing advantageously with the constitu-
tive TIS at +1. 5’ UTR mutations that change the initia-
tion codon have been reported as disease causing
mutations for other disorders [38,39]. However, our
study provides the first functional evidence that 5’UTR
of the ENG cause HHT.
The second sequence change found in this study is c.-
205A > C. This variant does not affect the ATG transla-
tion initiation. There is no specific sequence in the
endoglin promoter affected by this mutation based on in
silico studies. Family segregation study also suggests that
c.-205A > C is a benign sequence change (Table 1).
Moreover, studies with the -205A > C mutant construct
confirmed that this variant does not affect the expres-
sion level of ENG protein.
The c.-9G > A mutation has been found in three pro-
bands, one of whom is homozygous for the mutation.
Proband 6, her mother and proband 7 were heterozy-
gous for this mutation with mild clinical findings and
no organ involvement. Proband 8 with a homozygous
mutation had symptoms of HHT typical for a 78 year
old heterozygous mutation carrier. It might be specu-
lated that heterozygotes with this mutation might be
more mildly affected than typical HHT patients.
Although none of the heterozygous probands or affected
family members was found to have solid organ involve-
ment, no conclusion can be made from this small num-
ber of cases as to whether the epistaxis or oral/dermal
telangiectases resulting from this mutation are more
mild than typical.
The c.-9G > A mutation also creates a new TIS, yet
does not alter the reading frame. Based on viability in
the homozygous state, we suggest that the c.-9G > A
mutation results in reduced, but not absent, protein pro-
duction or function. The double construct study sup-
ports that the c.-9G > A mutation does not create a
strong TIS and the existing TIS is also being used for
translation. This confirms thel e a k i n e s so ft h ei n i t i a t i o n
of the translation. Given the possibly milder phenotype
in heterozygous patients, and viability in a homozygote
patient, we conclude that the c.-9G > A mutation may
represent a milder HHT mutation, which has never
been reported before.
In addition to the consequences in translation, the
pathogenic mutations at c.-9 and c.-127 may also have
effects in the transcriptional regulation of Endoglin. In
this sense, an in silico analysis using the MatInspector
program revealed that several putative consensus
motifs for transcription factors were either destroyed
or generated (see Additional File 1). More specifically,
the mutation c.-127C > T generates the disappearance
of consensus motifs for WHNF and EGRF family
members, while raises a new motif for the general
transcription factor IID. Moreover, the mutation c.-9G
> A generates the disappearance of several binding
sites for EGRF, HESF, EBOX, HIF or p53 family mem-
bers, while raises several motifs for p53, GCMF or
SRFF transcription factors. Finally, it is worth mention-
ing that many mutations leading to frameshift and
truncation may result in nonsense mediated decay and
therefore reduced mRNA levels [40]. In addition to the
effects on protein translation/processing analyzed here,
we cannot rule out the possibility that these ATG
mutations may also decrease mRNA stability, as pre-
viously described in HHT1 for several truncation
mutations of ENG [41].
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This study highlights two novel mutations in the 5’UTR
region of the ENG gene, c.-9G > A and c.-127C > T. In
vitro expression studies predict that these mutations
would result in reduced expression of the endoglin pro-
tein. Taken together, the clinical, co-segregation and
functional data suggest these mutations cause HHT in
the families studied.
A 78 year old with HHT who is shown to be homozy-
gous for c.-9G > A suggests that this mutations causes a
leakiness of transcription initiation and possibly a milder
clinical phenotype. This is the first report of an appar-
ently pathogenic mutation found in the homozygous
state in a patient with HHT. In summary, we detected
mutations in the 5’UTR region of the ENG gene in 8 of
154 unrelated patients with known or suspected HHT
in whom sequencing of the coding region and intron/
exon border region of ENG and ACVRL1 h a df a i l e dt o
identify a mutation. Analysis of the two mutations at
the protein level found in seven probands suggests the
involvement of the mutations in the pathogenesis of
HHT. The 5’UTR of the ENG gene should be included
in genetic testing for HHT to increase clinical
sensitivity.
Additional material
Additional file 1: Search results for the mutations of the endoglin
promoter in MatInspector. The pathogenic mutations at c.-9G > A and
c.-127C > T may also have effects in the transcriptional regulation of
endoglin. In silico analysis using the MatInspector program revealed that
several putative consensus motifs for transcription factors were either
destroyed or generated. Consensus prediction is indicated by a ‘Y’ or ‘N.’
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